A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis — AT03-001

Amyloidosis; Systemic Clinical Trial

Official title:
A Single Arm, Single Dose Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Select Organs in Patients With Systemic Amyloidosis

Status Completed

Clinical Trial Summary

This is a single center Phase 1 study is to evaluate the biodistribution of radiolabeled AT-03 in patients with systemic amyloidosis.

Clinical Trial Description

Eligible subjects will receive a single dose of radiolabeled AT-03, a fusion protein of serum amyloid P and a single chain Fc receptor. Repeat Positron Emission Tomography/Computed Tomography (PET/CT) scans will be performed over a ~7 day period to assess the biodistribution of AT-03 to amyloid-containing tissues in patients with systemic amyloidosis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05201911
Study type	Interventional
Source	Attralus, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	November 30, 2021
Completion date	September 6, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05951049` - A Study of AT-02 in Subjects With Systemic Amyloidosis.	Phase 2
Recruiting	`NCT05521022` - Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis	Phase 1
Active, not recruiting	`NCT04474938` - Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis	Phase 2
Terminated	`NCT02994784` - Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients	Phase 2
Recruiting	`NCT06192979` - Optimize First-line Treatment for AL Amyloidosis With t (11; 14)	N/A
Completed	`NCT03401372` - BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients	N/A